Metacrine Inc. (MTCR): Price and Financial Metrics Recent IPO


Metacrine Inc. (MTCR) Recent IPO

Today's Latest Price: $8.50 USD

0.23 (-2.63%)

Updated Nov 24 4:00pm

Add MTCR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MTCR Stock Price Chart Interactive Chart >

Price chart for MTCR

MTCR Price/Volume Stats

Current price $8.50 52-week high $16.19
Prev. close $8.73 52-week low $8.05
Day low $8.34 Volume 39,000
Day high $8.74 Avg. volume 95,614
50-day MA $0.00 Dividend yield N/A
200-day MA $0.00 Market Cap 220.63M

Metacrine Inc. (MTCR) Company Bio


Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.


MTCR Latest News Stream


Event/Time News Detail
Loading, please wait...

MTCR Latest Social Stream


Loading social stream, please wait...

View Full MTCR Social Stream

Latest MTCR News From Around the Web

Below are the latest news stories about Metacrine Inc that investors may wish to consider to help them evaluate MTCR as an investment opportunity.

Metacrine prices IPO at $13

Metacrine (MTCR) has priced its IPO of 6.54M at $13.00/share, for expected gross proceeds of ~$85M.Underwriters' over-allotment is an additional 981K shares. Trading kicks off September 16. Closing date is September 18.Previously: Metacrine sets IPO terms (Sept. 9)...

Seeking Alpha | September 16, 2020

Metacrine sets IPO terms

NASH biotech, Metacrine (MTCR) to raise $85M by offering 6.5M shares at a price range of $12 - $14.Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal, or GI, diseases. Most advanced program targets the farnesoid X receptor, or FXR,...

Seeking Alpha | September 9, 2020

Read More 'MTCR' Stories Here

MTCR Price Returns

1-mo -5.13%
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7363 seconds.